The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after ...

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that ...

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...